medigraphic.com
ISSN 1995-9427 (Impreso)

2021, Número 3

<< Anterior Siguiente >>

Invest Medicoquir 2021; 13 (3)


Índices de inflamación como predictores de daño pulmonar en pacientes recuperados de COVID-19

Reyes EL, Lage DA, Macías AC

Idioma: Español
Referencias bibliográficas: 33
Paginas: 1-19
Archivo PDF: 222.56 Kb.


RESUMEN

Introducción. La pandemia del nuevo coronavirus 2019 (COVID-19), ha afectado a más de 40 millones de personas en todo el mundo. La fase aguda de la enfermedad ha sido ampliamente descrita, sin embargo, existen pocos estudios en la fase de recuperación. La tercera parte de los pacientes recuperados quedan con lesiones inflamatorias pulmonares que pueden llevar a una fibrosis irreversible. El presente estudio evalúa tres marcadores de inflamación en pacientes recuperados de COVID-19 con y sin daño pulmonar, así como el efecto del tratamiento en dichos marcadores. Métodos. Se realizó un estudio piloto longitudinal prospectivo en 49 pacientes recuperados de COVID-19, 20 de ellos con daño pulmonar y 29 sin daño. Se les realizó hemograma completo, obteniéndose el conteo absoluto de neutrófilos (N), linfocitos (L) y plaquetas (P), para el análisis de la razón neutrófilos/linfocitos (NLR), la razón plaquetas/linfocitos (PLR) y el índice de inflamación inmune sistémica (SII). Resultados. El PLR y el SII estuvieron aumentados en los pacientes con daño pulmonar. El PLR fue el mejor índice para predecir el daño, niveles superiores o igual a 112.07, se asociaron con un incremento de 7 veces el riesgo. El tratamiento con prednisona disminuyó el PLR en los pacientes recuperados al mes de tratados. Conclusiones. El PLR y el SII son marcadores predictivos del daño pulmonar, siendo el PLR el que mejor discrimina a los pacientes con daño. Estos resultados sugieren que pudiera emplearse el tratamiento con prednisona en los pacientes recuperados con daño pulmonar y PLR superior o igual a 112.07.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. COVID-19 Weekly Epidemiological Update. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201020-weekly-epi-update-10.pdf. Accessed October 21, 2020.

  2. Li K, Wu J, Wu F, Guo D, Chen L, et al. The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia. Invest Radiol 2020;55: 00–00

  3. Zheng M, Gao Y, Wang G, Song G, Liu S, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cellular & Molecular Immunology 2020. https://doi.org/10.1038/s41423-020-0402-2

  4. Liu J, Li S, Liu J, Liang B, Wang X, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55 (2020) 102763. https://doi.org/10.1016/j.ebiom.2020.102763

  5. Fan Wang, Jiayan Nie, Haizhou Wang, Qiu Zhao, Yong Xiong, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. JID 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184346/pdf/jiaa150.pdf

  6. Wan S, Yi Q, Fan Sh, Lv J, Zhang X, et al. Relationships among Lymphocyte Subsets, Cytokines, and the Pulmonary Inflammation Index in Coronavirus (COVID-19) Infected Patients. British Journal of Haematology 2020: 189,428–437. doi: 10.1111/bjh.16659

  7. Francesca Salamanna, Melania Maglio, Maria Paola Landini & Milena Fini. Platelet functions and activities as potential hematologic parameters related to Coronavirus Disease 2019 (Covid-19. Platelets 2020, 31:5, 627-632, DOI: 10.1080/09537104.2020.1762852

  8. Yanli Liu, Wenwu Sun, Yanan Guo, Liangkai Chen, Lijuan Zhang, et al. Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study. Platelets 2020, DOI: 10.1080/09537104.2020.1754383

  9. Lolli C, Caffo O, Scarpi E, Aieta M, Conteduca V, Maines F et al. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. Front. Pharmacol 2016; 7:376. doi: 10.3389/fphar.2016.00376

  10. Howard R, Kanetsky P.A, Egan K.M. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Scientific Reports 2019; 9:19673. https://doi.org/10.1038/s41598-019-56218-z

  11. Takada T, et al. Added value of inflammatory markers to vital signs to predict mortality in patients suspected of severe infection. American Journal of Emergency Medicine. 2019. https://doi.org/10.1016/j.ajem.2019.11.030

  12. Kucuk H, Tecer D, Goker B, et al. Platelet/lymphocyte ratio and mean platelet volume in patients with granulomatosis with polyangiitis. Advances in Rheumatology 2020; 60:4 https://doi.org/10.1186/s42358-019-0110-8

  13. Çetinkaya ÖA, Çelik SU, Terzioğlu SG, Eroğlu A. The Predictive Value of the Neutrophil-to-Lymphocyte and Platelet-toLymphocyte Ratio in Patients with Recurrent Idiopathic Granulomatous Mastitis. Eur J Breast Health 2020; 16(1): 61-65.

  14. Paliogiannis P, Fois A G, Sotgia S, et al. Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives. Eur Respir Rev 2018; 27: 170113 [https://doi.org/10.1183/16000617.0113-2017]

  15. Palella E, Cimino R, Pullano S A, et al. Laboratory Parameters of Hemostasis, Adhesion Molecules, and Inflammation in Type 2 Diabetes Mellitus: Correlation with Glycemic Control. Int. J. Environ. Res. Public Health 2020, 17, 300; doi:10.3390/ijerph17010300

  16. Liu J, Liu Y, Xiang P, Pu L, Xiong H, et al. Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage. 2020. https://doi.org/10.1101/2020.02.10.20021584

  17. Tao Chen, Di Wu, Huilong Chen, Weiming Yan, Danlei Yang, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368:m1091. http://dx.doi.org/10.1136/bmj.m1091

  18. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, Dong W, Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study, Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2020.09.023.

  19. Liu BM, Yang QQ, Zhao LY, Xie W, Si XY (2020). Epidemiological characteristics of COVID-19 patients in convalescence period. Epidemiology and Infection 148, e108, 1–9. https://doi.org/10.1017/S0950268820001181

  20. Xuetao Cao. COVID-19: immunopathology and its implications for therapy. Nature reviews 2020. https://doi.org/10.1038/s41577-020-0308-3

  21. Geng Li, Yaohuao Fan, Yanni Lai, Tiantian Han, Zonghui Li, et al. Coronavirus Infections and Immune Responses. J Med Virol 2020; 92:424–432. doi: 10.1002/jmv.25685.

  22. Zhao G, Su Y, Sun X, et al. A comparative study of the laboratory features of COVID-19 and other viral pneumonias in the recovery stage. J Clin Lab Anal. 2020;00:e23483. https://doi.org/10.1002/jcla.23483

  23. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;1–4.

  24. Middleton EA, Weyrich AS, Zimmerman GA. Platelets in pulmonary immune responses and inflammatory lung diseases. Physiol Rev 96: 1211–1259, 2016. Published August 3, 2016; doi:10.1152/physrev.00038.2015

  25. Germolec DR, Shipkowski KA, Frawley RP, Evans E. Markers of Inflammation. Immunotoxicity Testing: Methods and Protocols, Methods in Molecular Biology, 2018: 1803(5) 57-77. https://doi.org/10.1007/978-1-4939-8549-4_5

  26. Wang Q, Ma J, Jiang Z, Ming l. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary embolism: a systematic review and meta-analysis. Int Angiol 2018;37:4-11. DOI: 10.23736/S0392-9590.17.03848-2)

  27. Fabrizio Galimberti, Jeffrey McBride, Megan Cronin, Yumeng Li, Joshua Fox, et al. Evidence-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19. Clinics in dermatology 2020. https://doi.org/10.1016/j.clindermatol.2020.05.003

  28. Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin N Am 2016; 42:157-176. ix-x.

  29. Xing X, Hu S, Chen M, et al. Severe acute respiratory infection risk following glucocorticosteroid treatment in uncomplicated influenza-like illness resulting from pH1N1 influenza infection: a case control study. BMC Infect Dis 2019;19, 1080.

  30. Stankus SJ, Dlugopolski M, Packer D. Management of Herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician 2000; 61:2437.

  31. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet Lond Engl 2020; 395:473-475.

  32. Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet Lond Engl 2020; 395:683-684.

  33. Pan American Health Organization. Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews. RAPID REVIEW, 22 September 2020. www.paho.org/coronavirus.




2020     |     www.medigraphic.com